Shamburg News · 8-K filed Oct 5, 2026, 8:30 AM EDT
Coya Therapeutics Completes Enrollment of 120 Patients in Phase 2/3 ALSTARS Trial of COYA 302
COYA · Coya Therapeutics, Inc.
- Other event
- Materiality: medium
On October 5, 2026, Coya Therapeutics announced full enrollment of the planned 120 patients in its Phase 2/3 ALSTARS Trial evaluating COYA 302 for amyotrophic lateral sclerosis. Topline data from the double-blind treatment phase are anticipated in early Q2 2027. Additional patients already in active screening may enroll if deemed eligible.
Source: SEC EDGAR, Form 8-K, Item 8.01, accession 0001193125-26-413218.
Written from the filing by Shamburg Markets. Figures are as reported by the company.